# ACURA PHARMACEUTICALS, INC. · Edgar & Edgarette company card

> Acura Pharmaceuticals saw revenue fall 56.2% in FY2021 to $2 million, operating margin -77.7% against a -3.8% median for pharmaceutical preparations, equity 20.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 786947 · fiscal year ended 2021-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/786947) · [JSON](https://www.pops4.com/boards/company/786947.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2M |
| Revenue growth, 1 year | -56.2% |
| Revenue growth per year | -14.8% |
| Operating margin | -77.7% (prior year -21.2%) |
| Net margin | -56.2% |
| Operating cash flow | −$742,000 |
| Capital spending | — |
| Free cash flow | — |
| Cash | $65,000 |
| Long-term debt | — |
| Total assets | $860,000 |
| Total equity | $178,000 |
| Equity ÷ assets | 20.7% |
| Return on equity | -493.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -1488.99 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, late quarterly report notice in the last 12 months; operating cash flow was negative (-$742K in FY2021); operating loss: a margin of -77.7% in FY2021; revenue is hard to predict: its 80% range is ±66%

## Edgarette's reading

Exposure: revenue $1.6M (FY2021). Experience: revenue down 56.2% on the year, down 14.8% a year over 4 years; operating margin -77.7%, down from -21.2%. Soundness: equity 20.7% of assets, return on equity -493.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $694K and $3.4M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $622K to $3.8M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -77.7% against a -3.8% median; growth -56.2% against 13.7%.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-27 ([filing](https://www.sec.gov/Archives/edgar/data/786947/000110465926036113/0001104659-26-036113-index.htm))
- Item NT 10-Q Late quarterly report notice: 4, latest 2026-11-06 ([filing](https://www.sec.gov/Archives/edgar/data/786947/000110465926123628/0001104659-26-123628-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/786947/000110465926121685/0001104659-26-121685-index.htm)
- 8-K · filed 2026-10-06 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/786947/000110465926114055/0001104659-26-114055-index.htm)
- 8-K · filed 2026-08-20 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/786947/000110465926099200/0001104659-26-099200-index.htm)
- 8-K · filed 2026-07-24 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/786947/000110465926086651/0001104659-26-086651-index.htm)
- 8-K · filed 2026-06-29 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/786947/000110465926078839/0001104659-26-078839-index.htm)
- 8-K · filed 2026-05-07 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000786947.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=786947

## Cite

POPS4, Edgar & Edgarette: ACURA PHARMACEUTICALS, INC. company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/786947. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

